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We defined the overall medical care cost by adding the
cost of surgery, the post-operative hospital stay and/or hospi-
talisation within one month after surgery.
Results For endometrial cancer, the surgical procedure cost for
robotic-assisted laparoscopy was C¼ 5.950 versus C¼ 4.950 for
conventional laparotomy. Considering the overall medical care,
the average cost of the in-patient treatment was C¼ 7.467
(median C¼ 6.302) for the robotic group (with average hospital
stay of 3,12 days), compared to C¼ 8.086 (median C¼ 7.024)
for the open-surgery group (with average hospital stay of 5,34
days). p value for the cost of surgeries is calculated to 0,37
while p value for the average stay is 0,00001.
Conclusion The cost of a robotic hysterectomy-BSOE-pelvic
lymphadenectomy exceeds the cost of the open-surgery for
endometrial cancer due to the higher cost of instruments and
equipment. However, when considering overall medical care,
conventional surgery for endometrial cancer is found 1,08
times more expensive than robotic-assisted surgery.
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Introduction/Background The diagnostic accuracy of endome-
trial biopsy has been related to the amount of tissue. In endo-
metrial cancer (EC) there is only moderate agreement on
tumor grade between preoperative endometrial sampling and
final diagnosis with the lowest agreement for grade 2 carci-
noma. Since the amount of preoperative endometrial tumor
tissue has not yet been related to the degree of discordance,
we aim to determine this relation with regard to final tumor
type and grade.
Methodology Within the European Network for Individualized
Treatment of Endometrial Cancer (ENITEC), 582 preoperative
endometrial biopsy samples of EC patients were retrospectively
collected and classified into low-grade (grade 1–2) and high-
grade carcinoma (grade 3). The endometrial tissue surface was
digitally calculated using ImageJ software and the correlation
between the amount of tissue and concordance of diagnosis
was calculated.
Results Agreement on tumor grade between preoperative endo-
metrial sampling and final diagnosis was 62.5%. Up- or down-
grading was found in respectively 27.1% and 10.3%.
Clinically relevant up- or downgrading was found in
respectively 7.8% and 27% of the cases. Premalignant endo-
metrial tissue contained less endometrium compared to malig-
nant endometrium (4.4 vs. 19.3 mm2,p=0.03). Serous EC
contained less endometrial tissue compared with grade 1–3
endometrioid EC (13.0 vs. 19.1 mm2,p=0.017). The median
endometrial tissue surfaces of grade 1-3 did not significantly
differ from each other (18.7 vs. 19.8 vs. 24.1 mm2). Samples
with a discordant diagnosis consisted of significantly more
endometrial tissue compared to the concordant group
(p=0.018).
Conclusion Based on postoperative diagnosis, there is no dif-
ference in the amount of endometrial tissue between the dif-
ferent endometrial grades. However, there is a tendency to
underestimate a sample with less and overestimate a sample
with more endometrial tissue. Awareness is especially needed,
in serous EC with in general less tissue.
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Introduction/Background Standard therapy for recurrent endo-
metrial cancer is chemotherapy. There is less conclusive evi-
dence about surgical treatment of recurrent endometrial
cancer. We investigated outcomes after surgical treatment for
recurrent endometrial cancer at our hospital and verified its
effectiveness.
Methodology We reviewed the medical records retrospectively
for patients who underwent surgical treatment for primary
recurrent endometrial cancer between September 2002 and
March 2016.
We evaluated clinicopathological characteristics, time to
recurrence, age at the time of surgical treatment for recur-
rence, the site of recurrence, residual tumor and postoperative
therapy of recurrent surgery, progression-free survival (PFS)
and overall survival (OS).
Results 18 patients were evaluated. The median follow-up was
28.9 months (12.7–134.2).
Median age was 65.5 (48–78) years old. The site of recur-
rence were lung 7, peritoneal dissemination 7, and lymph
nodes 5. 14 of 18 patients had underwent macroscopic com-
plete tumor resection. Median PFS was 18.1 months (0.9–
134.2) and median OS was 119.1 months (31.1–189.2).Prog-
nostic factors for surgical treatment of PFS were lung metasta-
ses (HR 0.18 [95% CI: 0.042–0.77], P<0.05), age at the time
of surgical treatment for recurrence (66 years or older) (HR
0.25 [95% CI: 0.07–0.95], P<0.05), and those of OS were
residual tumor (HR 10.6 [95% CI: 1.69–66.9], P<0.05), time
to recurrence(758 days or more) (HR 0.12 [95% CI: 0.02–
0.80], P<0.05).
Conclusion Surgical treatment of recurrent endometrial cancer
may be effective for patients who had longer time to recur-
rence and underwent macroscopic complete tumor resection.
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